RFA-DK-21-022: NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $375,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on December 21, 2021.
From the official notice on Grants.gov, last changed September 2, 2021. Checked November 7, 2026.
- Award ceiling$375,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsOptional
- Funded byNIDDK
- Median yearly award$529,546
- Typical project length4.5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-DK-21-022 were run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 7 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DK-21-022 in the NIH Guide.
Key dates
| Posted | September 1, 2021 |
|---|---|
| Deadline | December 21, 2021 |
| Archived by Grants.gov | January 26, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $529,546; it allows up to $375,000 per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) was established in July 2002 for the purpose of identifying genetic variation predisposing to Inflammatory Bowel Disease (IBD). Since its establishment and in collaboration with the International IBD Genetics Consortium, the NIDDK IBDGC has identified over 250 IBD susceptibility loci. However, for the great majority of these loci, the specific causal variants and effector genes have not yet been identified, and the biological mechanisms through which these variants influence IBD pathophysiology remain to be elucidated. The purpose of this FOA is to renew the IBDGC with a continued mission to characterize the genetic architecture of IBD and its sub-phenotypes, particularly in populations currently under-represented in IBD genomic studies, and to elucidate the biological mechanisms by which genetic variants influence IBD pathophysiology, phenotypes and outcomes, with the long-term goal of improving disease course prediction and treatment. The Genetic Research Centers (GRCs) of the IBDGC will serve as sites for enrollment of IBD patients, relatives and healthy controls, for laboratory-based studies on biological samples taken from these subjects, and for mechanistic studies of the variants identified and of the genes, proteins and pathways they impact. The Program Directors / Principal Investigators of the GRCs will serve as voting members of the Steering Committee of the IBDGC, which will be responsible for all operational decisions, which will be binding upon all members of the IBDGC.
Funded under RFA-DK-21-022 so far
NIH funded 7 projects under RFA-DK-21-022 in fiscal 2022 to 2026, at 7 institutions. The median yearly award was $529,546.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| University of Miami IBD Genetic Research Center: Understanding the Genetic Architecture of IBD in the South Florida community | University of Miami School of Medicine | 2026 | $541,049 |
| Integrative and longitudinal multi-omic risk assessment in inflammatory bowel disease progression | Emory University | 2026 | $557,918 |
| Montreal-Boston Collaborative GRC | Montreal Heart Institute | 2026 | $483,450 |
| Genomic and Immunologic Characterization of Inflammatory Bowel Disease and its Phenotypes | Sinai Health System | 2026 | $392,842 |
| Mount Sinai NYC Genetics Research Center: Multi-omic integration across data-types, cell niches and populations | Icahn School of Medicine at Mount Sinai | 2026 | $595,725 |
| IBD Gene Mapping by Clinical and Population Subset | Rutgers Biomedical and Health Sciences | 2026 | $457,627 |
| Determining genomic and host-environment contributions to IBD phenotypes | Cedars-Sinai Medical Center | 2026 | $569,075 |
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before
From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 273 | $345 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 187 | $272 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 209 | $238 million |
| The Washington University | Missouri | 187 | $227 million |
| The Regents of the University of California, San Francisco | California | 176 | $208 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DK-21-022 still open?
No. It closed on December 21, 2021.
Who can apply for NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01 Clinical Trial Optional)?
Closed December 21, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $375,000 each.
Who has been funded under RFA-DK-21-022?
NIH RePORTER lists 7 projects funded under RFA-DK-21-022 in fiscal 2022 to 2026, at 7 institutions. The most were at University of Miami School of Medicine, Emory University, Montreal Heart Institute.
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)